Takeda completes acquisition of nimbus therapeutics' tyk2 program subsidiary

Osaka, japan & cambridge, mass.--(business wire)--takeda (tse:4502/nyse:tak) today announced that it has completed an acquisition of all shares of nimbus lakshmi, inc. (“lakshmi”) from nimbus therapeutics, llc (“nimbus”), on february 8, 2023 (est), as set forth in the share purchase agreement, following clearance from the united states federal trade commission and a satisfaction of other closing conditions. the agreement had been announced on december 13, 2022: “takeda to acquire 100% ownership of nimbus therapeutics' tyk2 program subsidiary”.
TAK Ratings Summary
TAK Quant Ranking